Want to see DYN full AI Analyst Report?
Dyne Therapeutics (DYN) AI Stock Analysis
Dyne Therapeutics
(NASDAQ:DYN)
The score is held down primarily by weak financial performance (no revenue, widening losses, and rising cash burn), partially offset by a comparatively supportive balance sheet. Technicals are mixed with only modest near-term momentum. Valuation remains challenging due to ongoing losses, while the recent positive DM1 clinical data provides a meaningful but not decisive upside catalyst.
Dyne Therapeutics (DYN) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $3.46B
- Dividend Yield
- ―
- Average Volume (3M)
- 2.81M
- Price to Earnings (P/E)
- -5.6
- Beta (1Y)
- 1.61
- Revenue Growth
- ―
- EPS Growth
- 13.71%
- Country
- US
- Employees
- 289
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Dyne Therapeutics Business Overview & Revenue Model
Company Description
Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders. Utilizing its proprietary FORCE platform, which is engineered to deliver disease-modifying therapeutics, the...
How the Company Makes Money
Dyne Therapeutics primarily generates revenue from collaboration and partnership arrangements rather than product sales (given its clinical-stage status). These arrangements can include upfront payments, research funding and cost reimbursements, and...
Dyne Therapeutics Financial Statement Overview
Summary
Weak financial performance driven by no meaningful revenue, widening net losses (to roughly -$605M TTM), and accelerating cash burn (operating cash flow around -$565M TTM). The balance sheet provides some offset with sizable equity (~$931M TTM) and low leverage ratios, though debt has increased sharply in TTM (~$244M).
Income Statement
12Very NegativeBalance Sheet
62PositiveCash Flow
18Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -1.07M | -2.05M | -2.24M | -2.46M | 0 | 0 |
| EBITDA | -577.74M | -437.97M | -315.75M | -234.26M | -163.50M | -148.20M |
| Net Income | -604.92M | -446.21M | -317.42M | -235.94M | -168.10M | -149.29M |
Balance Sheet | ||||||
| Total Assets | 1.23B | 1.19B | 691.23M | 165.08M | 306.32M | 425.66M |
| Cash, Cash Equivalents and Short-Term Investments | 1.13B | 1.11B | 642.27M | 123.10M | 256.01M | 376.57M |
| Total Debt | 244.28M | 20.28M | 23.99M | 27.41M | 30.48M | 32.64M |
| Total Liabilities | 303.87M | 214.83M | 61.40M | 73.79M | 53.96M | 57.47M |
| Stockholders Equity | 930.93M | 972.13M | 629.84M | 91.29M | 252.36M | 368.20M |
Cash Flow | ||||||
| Free Cash Flow | -568.76M | -405.13M | -294.75M | -188.89M | -156.71M | -123.18M |
| Operating Cash Flow | -564.53M | -403.21M | -292.37M | -188.16M | -153.65M | -119.56M |
| Investing Cash Flow | -7.50M | -28.75M | -204.08M | 83.31M | 87.20M | -137.89M |
| Financing Cash Flow | 914.24M | 890.31M | 809.89M | 54.32M | 37.39M | 157.82M |
Dyne Therapeutics Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DYN, the sentiment is Negative. The current price of 17.36 is above the 20-day moving average (MA) of 16.30, below the 50-day MA of 17.86, and below the 200-day MA of 19.33, indicating a neutral trend. The MACD of 0.08 indicates Negative momentum. The RSI at 52.75 is Neutral, neither overbought nor oversold. The STOCH value of 78.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DYN.
Dyne Therapeutics Risk Analysis
Dyne Therapeutics disclosed 83 risk factors in its most recent earnings report. Dyne Therapeutics reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
0 New RisksDyne Therapeutics Peers Comparison
Overall Rating
SRPT58Neutral
PTCT56Neutral- DYN50Neutral
WVE45Neutral
EWTX44Neutral
SLDB39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| SRPT | 58Neutral | $1.96B | -13.19 | -9.96% | ― | -20.44% | -349.84% |
| PTCT | 56Neutral | $5.69B | -52.65 | 57.10% | ― | -35.05% | -113.73% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| DYN | 50Neutral | $3.37B | -5.57 | -64.30% | ― | ― | 13.71% |
| WVE | 45Neutral | $706.08M | -3.38 | -44.48% | ― | -35.07% | -45.17% |
| EWTX | 44Neutral | $4.09B | 4.06 | -39.01% | ― | ― | -18.88% |
| SLDB | 39Underperform | $673.37M | -4.56 | -72.28% | ― | ― | 31.81% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DYN | Dyne Therapeutics, Inc. | 17.36 | -1.00 | -5.45% | |
| SRPT | Sarepta Therapeutics Inc. | 17.57 | -0.06 | -0.34% | |
| PTCT | PTC Therapeutics | 65.67 | -6.11 | -8.51% | |
| WVE | Wave Life Sciences Pte. Ltd | 3.22 | -4.64 | -59.03% | |
| SLDB | Solid Biosciences | 6.18 | 2.12 | 52.22% | |
| EWTX | Edgewise Therapeutics, Inc. | 38.87 | 21.71 | 126.52% |
Dyne Therapeutics Corporate Events
Dyne Therapeutics Highlights New ACHIEVE DM1 Trial Data
PositiveOn September 29, 2026, Dyne Therapeutics reported additional one-year clinical data from the multiple ascending dose portion of its Phase 1/2 ACHIEVE trial of zeleciment basivarsen for myotonic dystrophy type 1, showing sustained functional, strength...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 05, 2026